Recommend to a friend

Current and Emerging JAK Inhibitors

A variety of agents are in late-stage trials for the management of myelofibrosis (MF), targeting different cellular processes. This module explains the mechanism of action and clinical results of current and emerging therapies. Strategies to prevent, monitor, and manage treatment related adverse effects are also discussed. Learn to apply shared-decision making to develop individualized, patient-centric treatment plans considering healthcare inequities